New Research Reports

We maintain our SELL Rating on the Stock.

NOCIL’s 2QFY26 was weak, with revenue declining 12% YoY to INR3.2b. EBITDA also declined 44% due to continued pricing pressure in the domestic market.

Pidilite Industries (PIDI) reported consolidated revenue growth of 10% YoY (in line) in 2QFY26. Standalone revenue grew 10% YoY, with underlying volume growth (UVG) of 10% (est. 7%).

Q2FY26 Chemicals Business drives growth- Revenues grew 6% YoY to 3,534.5 crore driven by the Chemicals business (46% of the revenues) which reported a growth of 23% YoY to 1,667 crore. While technical textiles (13% of the revenue) and Packaging films (39% of revenues) reported a decline of 11% and 1% to 474.3 crore and 1,408 crore respectively. Consolidated EBITDA stood at 774.2 crore, up 44% YoY, translating to margins of 21.3%, up ~560 bps YoY driven by the Chemical business (EBIT) which stood at 29%, up ~1100 bps YoY. Moreover, PAT for...

Near-term performance is expected to remain muted, as pricing pressure in key product categories and elevated input costs continue to weigh on margins.

SRF delivered results in line with our expectations primarily owing to healthy performance in specialty chemicals and higher pricing of refrigerant gases. Higher volumes especially in HFCs also contributed to the growth. While Revenue grew by 6% YoY, EBITDA and PAT grew by impressive rates of 44% and 93% respectively. The chemicals business registered strong revenue growth of 23% YoY along with ~1080 bps of YoY margin improvement to 28.9%. Although some orders have been deferred on the agro side, we expect SRF to recoup the same in H2FY26. The Fluorochemicals part of the business was elevated by...

...

SRF delivered a strong 2QFY26, with EBIT surging 55% YoY, fueled by a robust 96%/44% YoY jump in the chemicals/performance films & foil (PFF) businesses, despite ongoing global headwinds.

Rossari Biotech continues to execute well operationally, leveraging R&D intensity and export expansion to offset pricing headwinds.

Fineotex Chemical Ltd. has announced that its Board of Directors will meet on September 27, 2025, to consider several key proposals, including the declaration of an interim dividend, the sub-division or split of equity shares with a face value of INR 2 each.

SRF held a conference call to clarify on the quota regime for refrigerant gases. Companies will be allocated product wise or GWP based quotas, with quota calculations eventually to expressed in GWP terms.

We expect the company to sustain robust growth over FY27E, led by stronger volume offtake in SDA segment driven by Euro-7 demand, scale-up of agro and pharma intermediates, and increasing contribution from electrolyte salts.

SRF is set to benefit from regulatory shifts and evolving global consumption patterns, particularly under the Kigali Amendment. This will be led by its fully backwardintegrated operations, robust supply chains, and strong international presence.

We maintain a constructive stance on Vinati Organics’ long-term outlook, supported by the expansion in ATBS capacities, improved utilization in Antioxidant segment and incremental contribution from the Veeral Organics facility, cementing its position in high-margin segments, leading to improved operating leverage and diversified revenue streams.

We believe the outlook remains positive, with strong growth visibility across agrochemicals, pharma, and polymers, while personal care should deliver steady performance.

*over or under performance to benchmark index Pidilite Industries is a pioneer in the adhesives, sealants and construction chemicals business. The company serves the consumer and industrial segments with innovative...

IPO NOTE

SRF Ltd manufactures and sells textiles, chemicals, films and polymers through four business segments Technical, Chemicals, Packaging and Others with diverse product offerings and operations. In Q1FY26, revenue from operations grew 9.9% YoY to Rs. 3,739cr, supported by...

Due to the recent correction in stock performance along with strong visibility from ATBS, new product ramp-up, and capacity expansion, we upgraded Vinati Organics (VO IN) to BUY' with a target price of Rs2,091, valuing the stock at 40x FY27 EPS. The company reported revenue of Rs5.4bn in Q1FY26, reflecting a modest 3.3% YoY increase but a sharp 16% sequential decline. Management has guided for ~15% revenue growth in FY26, led by an expected 20% increase in volumes, with EBITDA margins projected at ~27%. ATBS, the company's flagship high-margin product, continued to deliver robust growth and remains...

Vinati Organics (VO) reported a strong operated performance in 1QFY26, as EBITDA surged 33% YoY to INR1.7b. Gross margin expanded 710bp to 52%, while EBITDAM expanded 670bp YoY to 30.6%. PAT grew 31% YoY to INR1.1b (our est. INR940m).